Emtriva Dosage
Generic name: emtricitabine
Dosage form: capsule, oral solution
This dosage information does not include all the information needed to use Emtriva safely and effectively. See full prescribing information for Emtriva.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Adult Patients (18 years of age and older)
- EMTRIVA capsules: one 200 mg capsule administered once daily orally.
- EMTRIVA oral solution: 240 mg (24 mL) administered once daily orally.
Pediatric Patients (0–3 months of age)
- EMTRIVA oral solution: 3 mg/kg administered once daily orally.
Pediatric Patients (3 months through 17 years)
- EMTRIVA oral solution: 6 mg/kg up to a maximum of 240 mg (24 mL) administered once daily orally.
- EMTRIVA capsules: for children weighing more than 33 kg who can swallow an intact capsule, one 200 mg capsule administered once daily orally.
Dose Adjustment in Adult Patients with Renal Impairment
Significantly increased drug exposures were seen when EMTRIVA was administered to patients with renal impairment [See Clinical Pharmacology (12.3)]. Therefore, the dosing interval or dose of EMTRIVA should be adjusted in patients with baseline creatinine clearance <50 mL/min using the following guidelines (see Table 1). The safety and effectiveness of these dose adjustment guidelines have not been clinically evaluated. Therefore, clinical response to treatment and renal function should be closely monitored in these patients.
| Creatinine Clearance (mL/min) | ||||
|---|---|---|---|---|
| Formulation | ≥50 mL/min | 30–49 mL/min | 15–29 mL/min | <15 mL/min or on hemodialysis* |
|
||||
| Capsule (200 mg) |
200 mg every 24 hours |
200 mg every 48 hours |
200 mg every 72 hours |
200 mg every 96 hours |
| Oral Solution (10 mg/mL) |
240 mg every 24 hours (24 mL) |
120 mg every 24 hours (12 mL) |
80 mg every 24 hours (8 mL) |
60 mg every 24 hours (6 mL) |
Although there are insufficient data to recommend a specific dose adjustment of EMTRIVA in pediatric patients with renal impairment, a reduction in the dose and/or an increase in the dosing interval similar to adjustments for adults should be considered.
